GENE ONLINE|News &
Opinion
Blog

Sanofi
Sanofi Licenses ABL Bio’s Bispecific Antibody for Parkinson’s Disease
2022-01-13
Sanofi Bets $1 Billion on Preclinical Next-gen Immunotherapies
2021-12-22
Sanofi Bets on Baidu’s Algorithm to Develop mRNA-Based Therapeutics
2021-11-23
Sanofi, Regeneron’s Dupixent Shines in Phase 3 Trial for Prurigo Nodularis
2021-10-25
Sanofi Abandons mRNA-Based COVID-19 Vaccine Plan but Indian Biotechs March On
2021-09-28
WHO Recommends the Use of Sanofi’s and Roche’s Rheumatoid Arthritis Drugs to Cut COVID-19 Deaths
2021-07-12
Venglustat’s Phase 2/3 Trial Failure Pushes Sanofi to Drop Kidney Disease Program
2021-06-02
Sanofi, GSK Report Positive Trial Data for COVID-19 Vaccine
2021-05-18
Sanofi to Go After mRNA Based Cancer Treatments, Acquires Cambridge Startup for $470 Million
2021-04-12
Sanofi Joins Hands with German Biotech to Develop Improved AAV Capsids for Gene Therapies
2021-02-28
Libtayo’s Second Approval in One Month Sets Up Lung Cancer Duel with Merck’s Keytruda
2021-02-24
FDA Okay of Regeneron’s PD-1 Inhibitor Marks Entry of First Immunotherapy for Advanced Basal Cell Carcinoma
2021-02-12
Sanofi Looks to Bolster Immunology Pipeline By Acquiring Kymab for $1.5 Billion
2021-01-13
Sanofi/GSK Vaccine Delayed Due to Poor Immunogenicity in Older Adults
2020-12-15
Sanofi Offers to Buy Kiadis Pharma to Advance Immuno-Oncology Research
2020-11-03
1 2
LATEST
Biotech Showcase 2022: Healing the Psyche with Psychedelia
2022-01-17
Sex Dimorphism in Obesity and the Impact of Estrogen Hormone Therapy on Cardiometabolic Health
2022-01-17
ARM 2022: Industry Briefs on Cell and Gene Therapies
2022-01-17
Study Reveals a Form of Four-Stranded DNA that Links Protein Deficiency and Premature Aging
2022-01-17
Shanghai’s Everest Medicines Licenses Covid-19 Oral Antivirals from Singapore’s National Drug Discovery Platform
2022-01-17
Digital Health Programme to Connect British and Taiwanese Leaders
2022-01-17
Pfizer: Pneumonia Shot Can Be Given with COVID-19 Vaccine in Older Adults
2022-01-16
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!